hypermutation on neutralization and binding in the PGT121 family of broadly
neutralizing HIV antibodies. PLoS Pathog. 9 , e1003754.
Sok, D., Doores, K.J., Briney, B., Le, K.M., Saye-Francisco, K.L., Ramos, A.,
Kulp, D.W., Julien, J.P., Menis, S., Wickramasinghe, L., et al. (2014). Promis-
cuous glycan site recognition by antibodies to the high-mannose patch of
gp120 broadens neutralization of HIV. Sci. Transl. Med. 6 , 236ra63.
Steichen, J.M., Kulp, D.W., Tokatlian, T., Escolano, A., Dosenovic, P., Stan-
field, R.L., McCoy, L.E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. (2016).
HIV vaccine design to target germline precursors of glycan-dependent broadly
neutralizing antibodies. Immunity45,Published online on September 8, 2016.
http://dx.doi.org/10.1016/j.immuni.2016.08.016.
Stewart-Jones, G.B., Soto, C., Lemmin, T., Chuang, G.Y., Druz, A., Kong, R.,
Thomas, P.V., Wagh, K., Zhou, T., Behrens, A.J., et al. (2016). Trimeric HIV-1-
Env structures define glycan shields from clades A, B, and G. Cell 165 ,
813–826.
Stills, H.F., Jr. (2005). Adjuvants and antibody production: dispelling the myths
associated with Freund’s complete and other adjuvants. ILAR J. 46 , 280–293.
Victora, G.D., and Nussenzweig, M.C. (2012). Germinal centers. Annu. Rev.
Immunol. 30 , 429–457.
von Boehmer, L., Liu, C., Ackerman, S., Gitlin, A.D., Wang, Q., Gazumyan, A.,
and Nussenzweig, M.C. (2016). Sequencing and cloning of antigen-specific
antibodies from mouse memory B cells. Nat. Protoc.http://dx.doi.org/10.
1038/nprot.2016.102.
Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L.,
Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al.; Protocol G Principal In-
vestigators (2009). Broad and potent neutralizing antibodies from an African
donor reveal a new HIV-1 vaccine target. Science 326 , 285–289.
Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B.,
Phogat, S.K., Poignard, P., and Burton, D.R. (2010). A limited number of anti-
body specificities mediate broad and potent serum neutralization in selected
HIV-1 infected individuals. PLoS Pathog. 6 , e1001028.
Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P.,
Wang, S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al.; Protocol G Principal
Investigators (2011). Broad neutralization coverage of HIV by multiple highly
potent antibodies. Nature 477 , 466–470.
Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonza-
lez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. (2003). Antibody neutral-
ization and escape by HIV-1. Nature 422 , 307–312.
West, A.P., Jr., Scharf, L., Scheid, J.F., Klein, F., Bjorkman, P.J., and Nussenz-
weig, M.C. (2014). Structural insights on the role of antibodies in HIV-1 vaccine
and therapy. Cell 156 , 633–648.
Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou,
T., Schmidt, S.D., Wu, L., Xu, L., et al. (2010). Rational design of envelope iden-
tifies broadly neutralizing human monoclonal antibodies to HIV-1. Science
329 , 856–861.
Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo,
N.S., Louder, M., McKee, K., et al.; NISC Comparative Sequencing Program
(2011). Focused evolution of HIV-1 neutralizing antibodies revealed by struc-
tures and deep sequencing. Science 333 , 1593–1602.
Wu, X., Zhang, Z., Schramm, C.A., Joyce, M.G., Kwon, Y.D., Zhou, T., Sheng,
Z., Zhang, B., O’Dell, S., McKee, K., et al.; NISC Comparative Sequencing Pro-
gram (2015). Maturation and Diversity of the VRC01-Antibody Lineage over 15
Years of Chronic HIV-1 Infection. Cell 161 , 470–485.
Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.Y.,
Longo, N.S., and Dimitrov, D.S. (2009). Germline-like predecessors of broadly
neutralizing antibodies lack measurable binding to HIV-1 envelope glycopro-
teins: implications for evasion of immune responses and design of vaccine im-
munogens. Biochem. Biophys. Res. Commun. 390 , 404–409.
Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid,
J.F., Shi, W., Xu, L., et al. (2010). Structural basis for broad and potent neutral-
ization of HIV-1 by antibody VRC01. Science 329 , 811–817.1458 Cell 166 , 1445–1458, September 8, 2016